Article

Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes.

Medical Center, Patient Support and Services Building Suite G-400, University of California-Davis, 4150 V Street, Sacramento, CA 95817, USA.
Journal of Clinical Endocrinology &amp Metabolism (Impact Factor: 6.31). 03/2006; 91(2):485-91. DOI: 10.1210/jc.2005-1338
Source: PubMed

ABSTRACT Overweight and obesity are overrepresented in adolescents with type 1 diabetes mellitus (T1DM). Exogenous insulin administration often poorly reproduces normal insulin patterns and may less effectively regulate leptin and ghrelin, two hormones involved in the control of appetite and adiposity.
The objective of the study was to determine whether insulin regimens that better replicate normal insulin patterns and augment postprandial nutrient disposal may help normalize leptin and ghrelin and improve body weight regulation.
Ten young women with T1DM were studied in this 2-wk prospective, balanced crossover-design study at the University of California, Davis.
Participants received either a single injection of regular + NPH insulin (R+N) or two mealtime injections of Lispro insulin in randomized order on 2 separate days. Meal composition and total insulin administered were the same on both treatment days.
Plasma glucose, insulin, leptin, and ghrelin concentrations were monitored over the 10-h study period.
Lispro produced two distinct mealtime peaks of insulin, compared with one prolonged rise with R+N. Lispro reduced postprandial hyperglycemia and total glucose area under the curve. Leptin increased more on the Lispro (2.7 +/- 0.7 vs. 0.7 +/- 0.5 ng/ml, P = 0.02). Ghrelin was more suppressed after lunch with Lispro (P = 0.004).
Injection of Lispro insulin with meals produces more physiological insulin patterns, better glucose control, and improved leptin and ghrelin regulation than R+N. More closely mimicking normal insulin, leptin, and ghrelin responses to meals with fast-acting insulin may have implications for body weight regulation in T1DM.

0 Bookmarks
 · 
52 Views
  • DMW - Deutsche Medizinische Wochenschrift 12/2006; 131. DOI:10.1055/s-2006-956285 · 0.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since 1996, genetic engineering has allowed modifications of insulin yielding to multiple modified insulins with different pharmacokinetic and/or pharmacodynamic properties. Molecules with maintained pharmacodynamic and modified pharmacokinetic profiles have been selected. Currently available rapid-acting analogues (lispro, aspart and glulisine) achieve plasma peak concentrations about twice as high and within approximately half the time compared with regular human insulin thus closely mimicking the physiological insulin response to a meal. Long-acting analogues (glargine and detemir) ensure the steady supplement of basal insulin plasma levels, with a plateau type of profile. Main analytical pitfalls of commercially human insulin immunoassays include crossreactivity with analogues and their metabolites. These crossreactivities are of great concern for interpreting insulin levels in patients treated with analogues. The development of more specific analytical methods to quantify separately the concentrations of endogenous insulin, rapid-acting and long-acting analogues and metabolites would be of utmost importance: (1) to further understand long-acting analogue variability in terms of efficiency; (2) to perform analogue kinetic studies; (3) to measure analogues in routine toxicology (forensic medicine) and (4) to assess intact glargine or glargine metabolite in vivo toxicity: recent debates about glargine safety have highlighted the lack of data about metabolite status (proportion of metabolized glargine and bioactivity of its metabolite). This goal could be achieved by specific immunoassay development or/and mass spectrometry analysis.
    Medecine Nucleaire 10/2010; 34(10):571-582. DOI:10.1016/j.mednuc.2010.07.014 · 0.16 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective The effects of fructose and glucose consumption on plasma acylation stimulating protein (ASP), adiponectin, and leptin concentrations relative to energy intake, body weight, adiposity, circulating triglycerides, and insulin sensitivity were determined. Design and Methods Thirty two overweight/obese adults consumed glucose- or fructose-sweetened beverages (25% energy requirement) with their ad libitum diets for 8 weeks, followed by sweetened beverage consumption for 2 weeks with a standardized, energy-balanced diet. Plasma variables were measured at baseline, 2, 8, and 10 weeks, and body adiposity and insulin sensitivity at baseline and 10 weeks. ResultsFasting and postprandial ASP concentrations increased at 2 and/or 8 weeks. ASP increases correlated with changes in late-evening triglyceride concentrations. At 10 weeks, fasting adiponectin levels decreased in both groups, and decreases were inversely associated with baseline intra-abdominal fat volume. Sugar consumption increased fasting leptin concentrations; increases were associated with body weight changes. The 24-h leptin profiles increased during glucose consumption and decreased during fructose consumption. These changes correlated with changes of 24-h insulin levels. Conclusions The consumption of fructose and glucose beverages induced changes in plasma concentrations of ASP, adiponectin, and leptin. Further study is required to determine if these changes contribute to the metabolic dysfunction observed during fructose consumption.
    Obesity 12/2013; 21(12). DOI:10.1002/oby.20437 · 4.39 Impact Factor

Full-text (2 Sources)

Download
38 Downloads
Available from
May 21, 2014